Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2021 / Cilt: 27 - Sayı: 3

Clinical Course of Untreated and Treated Chronic Hepatitis B in Pregnant Patients: A Prospective Study

Sayfa
221–226
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

As a result, we successfully prevented perinatal HBV transmission by close monitoring of participant pregnant women and starting antiviral therapy when needed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: Implementation of strategies to prevent vertical transmission is highly important steps in reducing the global burden of chronic hepatitis B.
📊
Temel Bulgular & Veri:STUDY DESIGN: HBsAg-positive pregnants were prospectively enrolled from 2013 to 2016 and antiviral therapy was administered to eligible patients.
💡
Sonuç & Katkı:As a result, we successfully prevented perinatal HBV transmission by close monitoring of participant pregnant women and starting antiviral therapy when needed.
🔬Tür:Araştırma Makalesi
📍Kapsam:2013 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: Implementation of strategies to prevent vertical transmission is highly important steps in reducing the global burden of chronic hepatitis B. We conducted this prospective study to observe the clinical course and outcomes of untreated and treated HBV in pregnant. STUDY DESIGN: HBsAg-positive pregnants were prospectively enrolled from 2013 to 2016 and antiviral therapy was administered to eligible patients. Pregnancy and neonatal outcomes were determined in the treated (n=29) and untreated group (n=136). Active-passive immunoprophylaxis was administered to infants and they were tested for HBsAg. RESULTS: The risk factors for transmission (HBeAg positivity, history of previously-born HBsAg-positive child) were significantly higher in the treated group. All participants under treatment had sufficient viral suppression. Half of the pregnant women for whom the treatment was withheld at the postpartum period, experienced increased viral load. The treated group had significantly higher pre- and postpartum alanine aminotransferase levels more than the untreated group, although there were no significant differences in other biochemical parameters. There were no significant differences regarding fetal outcomes between the two groups. All infants were HBsAg-negative at seven months postpartum. CONCLUSION: While the untreated group included inactive carriers, there were more patients at risk for transmission of HBV to their offsprings in the treated group. Half of the pregnant women for whom the treatment was withheld at the postpartum period, experienced increased viral load. Antiviral therapy did not adversely affect the outcomes of infants. As a result, we successfully prevented perinatal HBV transmission by close monitoring of participant pregnant women and starting antiviral therapy when needed.

🔖

Bu Makaleye Atıf Yap

NARTER, F. K., BATIREL, A., NADIR, Y., KARSIDAG, A. Y. K., NADIR, A. (2022). Clinical Course of Untreated and Treated Chronic Hepatitis B in Pregnant Patients: A Prospective Study. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 27 - Sayı: 3, 221–226. https://ajindex.com/articles/525844

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Piratvisuth T. Optimal management of HBV infection during pregnancy. Liver Int. 2013;33 Suppl 1:188-94. Doi: 10.1111/liv.12060
  2. Kubo A, Schlager L, Marks AR, Laktriz D, Beumout C, Gabellini K, et al. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med. 2014;160(12):828-35. Doi:10.7326/M13-2529
  3. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261-83. Doi: 10.1002/hep.28156
  4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. Doi: 10.1016/j.jhep.2017.03.021
  5. Dunkelberg JC, Berkley EM, Thiel KW, Leslie KK. Hepatitis B and C in pregnancy: a review and recommendations for care. J Perinatol. 2014;34(12):882-91. Doi:10. 1038/jp.2014.167
  6. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2(1):50-7. Doi: 10.7150/ijms.2.50
  7. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19(2):e18-e25. Doi:10.1111/j.1365- 2893.2011.01492.x
  8. Bzowej NH. Optimal management of the Hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep. 2012;11(2):82-89. Doi:10.1007/s11901-012-0130-X
  9. Cui AM, Cheng XY, Shao JG, Li HB3, Wang XL, Shen Y, et al. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. BMC pregnancy childbirth. 2016;16:87. Doi:10.1186/s12884-016- 0884-1
  10. Chen JZ, Liao ZW, Huang FL, Su RK, Wang WB, Cheng XY, et al. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Sci Rep. 2017;7 (1):4132. Doi:10.1038/s41598-017-04479-X
  11. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502-7. Doi:10.1016/j.jhep.2014.04.038
  12. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother. 2008;42(11):1581-5. Doi: 10.1345/aph.1L083
  13. Yi P, Chen R, Huang Y, Zhou RR, Fan XG. Management of mother-to-child transmission of hepatitis B